| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
VP, Finance and Administration | Chief Financial Officer
1 company
Michael Morneau last filed a Form 4 in January 2021, as VP, Finance and Administration at VKTX. Michael Morneau's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 116,062 shares of VKTX. The VKTX filings lean toward selling, a net 21,551 shares.
Michael Morneau has 18 Form 4 filings on record from May 2015 to January 2021, all as VP, Finance and Administration at Viking Therapeutics (VKTX), 2015–2021.
The 26 reported transactions were 12 option or other derivative awards, 8 tax withholdings, 5 stock awards and 1 open-market sale.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $199K.
The only open-market sale was 21,551 shares of VKTX at an average $9.25 on May 31, 2018, about $199K.
Shares as reported in the last Form 4 for each company; the most recent is from January 2021. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| May 31, 2018 | VKTX Viking Therapeutics, Inc. | VP, Finance and Administration | Sell | 21,551 | $9.25 | $199,346.75 | -18.6% |